155 related articles for article (PubMed ID: 31818479)
1. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors.
Gumede NJ; Nxumalo W; Bisetty K; Escuder Gilabert L; Medina-Hernandez MJ; Sagrado S
Bioorg Chem; 2020 Jan; 94():103462. PubMed ID: 31818479
[TBL] [Abstract][Full Text] [Related]
2. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
3. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
4. New CYP17 hydroxylase inhibitors: synthesis, biological evaluation, QSAR, and molecular docking study of new pregnenolone analogs.
Al-Masoudi NA; Ali DS; Saeed B; Hartmann RW; Engel M; Rashid S; Saeed A
Arch Pharm (Weinheim); 2014 Dec; 347(12):896-907. PubMed ID: 25251696
[TBL] [Abstract][Full Text] [Related]
5. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
6. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
7. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
8. New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study.
Al-Masoudi NA; Kadhim RA; Abdul-Rida NA; Saeed BA; Engel M
Steroids; 2015 Sep; 101():43-50. PubMed ID: 26051784
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
[TBL] [Abstract][Full Text] [Related]
10. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
[TBL] [Abstract][Full Text] [Related]
11. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
12. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
Krug SJ; Hu Q; Hartmann RW
J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
[TBL] [Abstract][Full Text] [Related]
13. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
Haidar S; Hartmann RW
Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
15. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
16. CYP17A1 inhibitors in castration-resistant prostate cancer.
Gomez L; Kovac JR; Lamb DJ
Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
[TBL] [Abstract][Full Text] [Related]
17. [Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1].
Stulov SV; Dugin NO; Zharkova MS; Shcherbinin DS; Kuzikov AV; Shumyantseva VV; Misharin AY; Veselovsky AV
Biomed Khim; 2016; 62(1):38-44. PubMed ID: 26973185
[TBL] [Abstract][Full Text] [Related]
18. In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1.
Kędzierski J; Jäger MC; Naeem S; Odermatt A; Smieško M
Toxicol Appl Pharmacol; 2024 May; 486():116945. PubMed ID: 38688424
[TBL] [Abstract][Full Text] [Related]
19. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
20. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Clement OO; Freeman CM; Hartmann RW; Handratta VD; Vasaitis TS; Brodie AM; Njar VC
J Med Chem; 2003 Jun; 46(12):2345-51. PubMed ID: 12773039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]